Cara Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cara Therapeutics generated cash of -$92,078,000, which is less than the previous year. Cash used in financing activities reached the amount of $38,151,000 last year. Net change in cash is therefore -$10,466,000.
Cash Flow
| 2014 | -17.64M | -42K | 57.99M |
|---|---|---|---|
| 2015 | -21.47M | -91.67M | 75.59M |
| 2016 | -47.38M | 44.24M | 123K |
| 2017 | -54.82M | -35.8M | 87.92M |
| 2018 | -22.30M | -82.81M | 110.81M |
| 2019 | -109.22M | -30.51M | 142.60M |
| 2020 | -5.48M | -20.27M | 39.14M |
| 2021 | -60.08M | -4.75M | 46.60M |
| 2022 | -78.73M | 128.70M | 311K |
| 2023 | -92.07M | 43.46M | 38.15M |
CARA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 64.14M | 13.86M | 32.09M | 18.71M | 15.85M | 10.15M | 12.09M | 15.10M | 52.66M | 12.35M |
Operating activities | ||||||||||
Net income | -118.51M | -85.47M | -88.44M | 8.41M | -106.37M | -74.01M | -58.12M | -57.28M | -24.69M | -17.74M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 259K | 248K | 248K | 209K | 198K | 370K | 495K | 1.46M | 839K | 783K |
Stock-based compensation expense | 13.73M | 17.73M | 20.78M | 14.83M | 12.56M | 0 | 5.79M | 2.8M | 2.51M | 1.37M |
| Deferred income tax benefit | 13.73M | 17.73M | 20.78M | 14.83M | 12.56M | 0 | 5.79M | 2.8M | 2.51M | 1.37M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 436K | -3.26M | 1.02M | -277K | -197K | 0 | 85K | 0 | -264K | 0 |
Inventories | -438K | 201K | -2.58M | 277K | 197K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 3.27M | 5.67M | -1.02M | -2.78M | 6.04M | 5.11M | -3.02M | 0 | 3.32M | 0 |
Cash generated by operating activities | -92.07M | -78.73M | -60.08M | -5.48M | -109.22M | -22.30M | -54.82M | -47.38M | -21.47M | -17.64M |
Investing activities | ||||||||||
Purchases Of Investments | -113.60M | -95.68M | -208.79M | -232.88M | -286.08M | -337.85M | -127.39M | -68.64M | -91.65M | 0 |
Investments In Property Plant And Equipment | -2.37M | -43K | -39K | -349K | -18K | -73K | -58K | -717K | -20K | -42K |
Acquisitions Net | 0 | 752K | 70K | -118K | -1.38M | -1.81M | 41K | 0 | 0 | 0 |
Cash generated by investing activities | 43.46M | 128.70M | -4.75M | -20.27M | -30.51M | -82.81M | -35.8M | 44.24M | -91.67M | -42K |
Financing activities | ||||||||||
Common Stock Issued | 1.11M | 311K | 44.96M | 38.44M | 136.49M | 0 | 86.22M | 0 | 75.23M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 38.15M | 311K | 46.60M | 39.14M | 142.60M | 110.81M | 87.92M | 123K | 75.59M | 57.99M |
Net Change In Cash | -10.46M | 50.28M | -18.23M | 13.37M | 2.86M | 5.69M | -2.70M | -3.00M | -37.56M | 40.30M |
Cash at end of period | 53.68M | 64.14M | 13.86M | 32.09M | 18.71M | 15.85M | 9.38M | 12.09M | 15.10M | 52.66M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |